Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2015

Marketwired October 21, 2015

Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 (Bucillamine) in the Treatment of Acute Gout Flares

Marketwired September 30, 2015

Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2015

Marketwired May 20, 2015

Revive Therapeutics to Present at Marcum MicroCap Conference

Marketwired May 4, 2015

Revive Therapeutics Announces Positive Study Results From Its Research Collaboration With Rettsyndrome.org

Marketwired April 27, 2015

Bruce N. Cronstein, MD. Joins Revive Therapeutics as Medical Advisor

Marketwired April 15, 2015

Revive Therapeutics Enters Into Advisory Agreement with Spinnaker Capital Markets Inc.

Marketwired March 5, 2015

Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease

Marketwired February 26, 2015

Revive Therapeutics Announces Results for the Three and Six Months Ended December 31, 2014

Marketwired February 11, 2015

Revive Therapeutics Announces Initiation of a Phase 2A Study of REV-002 (Bucillamine) in Patients With Gout

Marketwired January 29, 2015

Revive Therapeutics Enters Into Research Collaboration With Rettsyndrome.org

Marketwired January 15, 2015

Revive Therapeutics Completes Prospectus Offering of Approximately $3,000,000

Marketwired December 18, 2014

Revive Therapeutics Prices and Files Final Prospectus for Equity Financing

Canada NewsWire December 5, 2014

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2014

Marketwired November 26, 2014

Revive Therapeutics Ltd. Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout

Marketwired November 26, 2014

Revive Therapeutics Ltd. Announces Receipt of Prospectus for Public Offering of Common Shares

Marketwired November 4, 2014

CORRECTION FROM SOURCE: Revive Therapeutics Ltd. Announcing Receipt for Preliminary Prospectus Is Pending

Marketwired November 4, 2014

Revive Therapeutics Ltd. Announces Public Offering of Common Shares

Marketwired November 3, 2014

Revive Therapeutics Ltd. Submits IND Application to the US FDA for the Clinical Development of Bucillamine for the Treatment of Gout

Marketwired October 30, 2014

Revive Therapeutics Ltd. Applies for Orphan Drug Designation to FDA for Treatment of Rett Syndrome

Marketwired October 28, 2014